

---

## Episurf Medical Q4 - Setting the stage for 2025

Redeye provides an in-depth review of Episurf Medical's Q4 report and events during and after the quarter. The report contained no major surprises; however, we are encouraged by the progression in the current FDA clearance process relating to Episealer MTP and the new distribution agreement with Joint Operations Ltd.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Episurf Medical Q4 - Setting the stage for 2025](#)